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Abstract

Department of Biomedical Engineering, University of
Akron, USA
1

Cancers of the oral and anogenital regions are a growing global health
problem that disproportionately impact women and men living in developing
countries. The high death rate in developing countries is largely due to the fact
that these countries do not have the appropriate medical infrastructure and
resources to support the organized screening and diagnostic programs that
are available in the developed world. Emerging optical diagnostics techniques,
such as optical spectroscopy, reflectance imaging, and fluorescence imaging,
are noninvasive techniques that are sensitive to multiple cancer biomarkers and
have shown the potential as a cost-effective and fast tool for diagnosis of early
precancerous changes in the cervix, oral cavity and anus. This paper provides
a review of current strategies for prevention, screening and diagnostic tests of
oral, cervical and anal cancers and development in optical diagnostic techniques
that could potentially be used to improve current practice in resource-limited
settings.
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cervical cancer, a preventable disease, too many women continue
to suffer even in resource-rich countries. More women’s life years
(death at a younger age) are lost with cervical cancer compared with
ovarian or breast cancer. Although less than 15,000 women in the
United States develop cervical cancer per year, greater than ten-fold
more are afflicted by precancerous conditions causing significant
morbidity from additional diagnostic tests, histological sampling and
surgical interventions. This toll occurs despite compliant surveillance
practices in resource-rich nations. Yet, these secondary cancer
prevention strategies are associated with tremendous expense ($8
billion/yr. in US), complicated logistics and significant morbidity.

The global burden of HPV-related cervical, anal and oral
cancers
Each year there are more than 750,000 cases of anogenital
and oropharyngeal cancers [1]. Of these human papillomavirus
(HPV)-induced cancers, there are 528,000 cases of cervical cancer
with 274,000 deaths per year (Figure 1a) [1]. The majority of these
cases (approximately 85%) occur in resource-poor countries [1,2].
Worldwide, cervical cancer is the second most common cancer
among women. The highest incidence rates of cervical cancer are
found in Central and South America, Africa and Asia where rates
exceed 50 cases per 100,000 women. Because of the lack of modern
prevention practices in these areas, the global mortality rate of
cervical cancer is estimated to increase by 25% during the next 10
years [2]. While the Pap test has substantially reduced the rate of

Each year, more than 650,000 new cases of head and neck
cancer are diagnosed worldwide, of which over one-third are oral
or oropharyngeal cancers [3,4]. As such, cancers of the head and
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Figure 1: Global cancer incidence and mortality rates for: (a) cervical cancer and (b) oral and oropharyngeal cancers. (Data extracted from the GLOBOCAN2012).
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the US, 80% of such cases are derived from squamous epithelium. Yet
in Japan, 80% are of glandular cell origin which is more difficult to
detect by current screening and diagnostic methods. Advanced cases
of anal cancer have a high mortality rate depending on the surgical
stage and nodal involvement [7]. Treatment regimens for anal cancer
are complicated and often alter quality of life [8].
Hence, HPV-related cancer remains a daunting problem for
public health, health care providers, insurers, patients and society.
The challenge is even greater for resource-poor countries.

Figure 2: Anal cancer (indicated with yellow arrows) and precancer (indicated
with blue arrow). The anal cancer is characterized by an irregular surface
contour and the presence of atypical blood vessels. The epithelium of the
precancer is thickened and opaque white (photo courtesy of Daron Ferris,
MD).

neck are the eighth most common type of cancer. Of these oral
cases, nearly two-thirds occur in resource-poor countries (Figure
1b) where diagnostic and therapeutic interventions are limited or
nonexistent. Tobacco and alcohol use are the main risk factors for
head and neck cancer. Consequently, men are at greater risk for this
cancer. However, the vast majority of oropharyngeal cancers and
many oral cancers are caused by infection with oncogenic HPV.
Moreover, the rate of HPV-induced oropharyngeal cancers is rising
at an alarming rate. Certain sexual practices have been implicated for
this increasing trend. But these cancers are extremely challenging to
detect. Approximately 90% of oropharyngeal cancers are buried in
the crypts of the tonsils or located at the base of the tongue [5,6].
Both of these sites are difficult to screen clinically due to location
and the tendency to elicit an uncomfortable gag reflex in the patient.
In contrast with HPV-induced disease located in other parts of the
body, oropharyngeal precancer lesions are not visually appreciated.
Consequently, virtually no screening testing is performed for
oropharyngeal cancer, particularly in resource-poor regions. Because
of no screening test, oropharyngeal cancers are usually detected
only when a large mass is noted. At this late stage, therapeutic cure
becomes exceedingly challenging. Despite various treatment options,
the 5-year survival rate is approximately 25% [5,6].
There were 30,400 cases of anal cancer diagnosed worldwide in
2002 [7]. In the United States, incidence rates of anal cancer and
severe anal precancers have increased twofold since the 1970s [7].
There are approximately 6,000 new cases of anal cancer diagnosed
annually in the US, the majority seen in women. Certain populations
are at an increased risk for anal cancer including immune
suppressed individuals (HIV+, organ transplant or other patients on
immunosuppressive pharmacologic agents), patients at behavioral
risk (men who have anal sex with men) and women with a history of
severe HPV-induced genital precancers or cancer. Although difficult
to estimate, there are likely 100 times more cases of anal pre-cancers
than anal cancer. Much like cervical cancer, anal cancer is preceded
by a pre-malignant condition providing an opportunity for early
detection and treatment (Figure 2). However, screening capabilities
or expertise in resource-poor countries are essentially nonexistent.
Therefore, in contrast with other HPV-induced cancers, more than
half of the cases of anal cancer are found in resource-rich nations. In
Submit your Manuscript | www.austinpublishinggroup.com

HPV is a highly contagious viral DNA organism and the most
common sexually transmitted infection. Essentially ubiquitous,
approximately 80% of individuals will become infected with HPV
during their lifetime. The peak prevalence of HPV infection is
between 15 to 25 years of age. While the majority of HPV infections
regress spontaneously without treatment, particularly in immunecompetent individuals, with continued viral persistence some
produce neoplasias. Facilitated by superficial trauma, HPV infects
both squamous and columnar epithelium. More than 100 types of
HPV exist with some being oncogenic and others considered nononcogenic. Based on regional tropism, approximately 40 HPV types
infect only the epithelium of the anogenital and oropharyngeal tracts.
Of these, approximately 16 are cancer causing types. HPV 16 is the
most frequent HPV type detected in cervical (in addition to vaginal
and vulvar), oral and anal cancers. HPV 16 and 18 cause approximately
70% of cervical cancer (Figure 3), 80-90% of anal cancer and nearly all
cases of oropharyngeal cancers [4,9-14]. Approximately 50% of high
grade cervical lesions (Cervical Intraepithelial Neoplasia (CIN) 2/3)
and 25% of CIN1 are caused by HPV 16 or 18. The remaining HPV
types cause condyloma (warts), premalignant diseases or cancer.
Infection may produce condyloma, precancers or cancer of the cervix,
vagina, and vulva in women, penis in men, and oropharynx and anus
in both sexes. Non-oncogenic HPV causes recurrent respiratory
papillomatosis, a debilitating and sometimes lethal upper airway
condition characterized by diffuse condyloma that may compromise
respiratory function [15]. An oncogenic HPV infection of immature
metaplastic epithelium in the cervical or anal transformation zone
initiates pathogenesis. With HPV persistence, cervical or anal cancer
precursor lesions or cancers may slowly arise [16]. While cervical
cancer usually results from the serial progression of CIN1 to CIN2

Figure 3: Cervical cancer (indicated by the yellow arrows) is seen on both the
anterior and posterior cervix in a 24 year old woman. The epithelial surface
is elevated, friable and yellowish in color. Atypical blood vessels are noted,
the hallmark of invasive cervical cancer. This cancer was caused by HPV 16
(photo courtesy of Daron Ferris, MD).
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to CIN3 and then cancer, some oncogenic HPV infections advance
directly to CIN3. However, the overall gradual development of these
neoplasias to cancer normally enables routine screening programs to
detect disease at early, universally curable stages.
Current strategies in prevention, screening and diagnostic
tests
Prevention- HPV vaccines
Using recombinant DNA virus-like-particles (VLPs) that cannot
convey genital infection, scientists have developed several human
papillomavirus (HPV) L1 VLP vaccines. The quadrivalent HPV
(qHPV) 6, 11, 16 and 18 L1 VLP vaccine (Gardasil®, Merck and
Co, Inc, White Station, NJ) and a bivalent HPV 16 and 18 L1 VLP
vaccine (Cervarix®, GSK, Rixensart, Belgium) prevent approximately
70% of all cervical cancers and the qHPV vaccine also prevents 90%
of anogenital warts. These two prophylactic HPV vaccines greatly
diminish the morbidity and mortality associated with HPV- induced
neoplasias of the anogenital tract [17-23]. The qHPV vaccine is 100%
effective in preventing anogenital neoplasia associated with the four
HPV vaccine types when administered to people naive to those HPV
types. Early adolescents (ages 11-12) who are not yet sexually active
represent the ideal target age for vaccination. However, the qHPV
may be given intramuscularly in 3 doses to both boys and girls ages
9-26. In addition to excellent efficacy, multiple clinical trials and
National Adverse Event surveillance systems (CDC Vaccine Adverse
Event Reporting System (VAERS) and CDC Vaccine Safety Data link
(VSD)) have demonstrated good qHPV vaccine safety. Studies have
determined HPV vaccination to be cost effective. The best cost saving
strategy occurs with maximum vaccine uptake. Widespread gender
neutral HPV vaccination also critically impacts HPV-related disease.
Both HPV vaccines are prophylactic and do not convey therapeutic
benefit. A novel nine-valent HPV vaccine is currently under review
by the FDA. This vaccine is expected to prevent 90% of cervical cancer
cases.
Great enthusiasm surrounded the advent of these two novel
primary cancer prevention vaccines. These prophylactic vaccines will
provide tremendous benefit by reducing the mortality and morbidity
associated with HPV-induced cervical cancers. Protection from
HPV-induced neoplasia is also afforded to the remainder of the lower
genital tract, including the vagina, vulva, perianal and anal region.In
addition, vaccination is expected to reduce the rate of head and neck
cancer and recurrent respiratory papillomatos is that are caused by
high risk and low risk HPV types, respectively. But despite extensive
marketing of the HPV vaccines in the United States and other
resource rich countries, vaccination rates remain embarrassingly
low. Poor qHPV vaccine uptake in the United States (33% for all 3
doses in 2012) has even raised concern from the Centers for Disease
Control and Prevention (CDC) [24]. Vaccine uptake is lowest in the
southeast United States where the highest rates of cervical cancer
mortality are also found. However, some countries using mandatory,
school based vaccination programs (i.e., Australia) have already
benefitted from the vaccine [25-28]. Yet, even there, the current HPV
vaccines will reduce but not totally eliminate HPV-induced cancers.
Unfortunately, distribution of HPV vaccines to resource-poor regions
has suffered from high cost and logistical issues. Hence, because of
slow vaccine uptake worldwide, a large number of unvaccinated
populations are exposed to the risk of other HPV types, traditional
Submit your Manuscript | www.austinpublishinggroup.com
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screening programs are still essential.
Screening
Papanicolaou test: The Papanicolaou (Pap) smear is the most cost
effective cancer screening test ever introduced. Where effectively
implemented, rates of cervical cancer have decreased by more than 70%.
While screening guidelines vary worldwide, generally women between
21 and 65 years of age are screened. Routine anal Pap screening is
also recommended for high-risk individuals [29-31]. The test involves
careful sampling of the uterine cervical or anal transformation zones
(squamous ectocervical, columnar endocervical, and interposed
metaplastic cells) using one or more cytologic collection devices.
Two types of Pap tests exist, the conventional Pap test and liquidbased Pap tests. While the collection methods are identical, with the
former test, cells are transferred directly to a glass slide then quickly
fixed at bedside in the exam room. Using liquid-based testing, after
sampling, the cells are instead transferred to a liquid preservative
and the slide is later processed in the laboratory. Both types are Pap
stained and then examined microscopically by trained health care
providers. Automated, computer-based technology is also used to
examine Pap tests for quality control (re-read of negative test results)
or primary screening purposes. Cytologic diagnoses are rendered
using the Bethesda System terminology as NILM, ASCUS, ASC-H,
AGC, LSIL, HSIL, AIS, and cancer. The conventional cervical Pap test
is approximately 50% sensitive at detecting cervical neoplasia and the
liquid-based test is approximately 80% sensitive. Using residual cells,
the latter collection method also permits co-testing for oncogenic
HPV either as a reflex triage test for women with Atypical Squamous
Cells of Undetermined Significance (ASCUS) results or in primary
screening (co-testing) with the Pap test for women greater than 30
years of age. The sensitivity of the anal Pap test is much lower and
the rate of unsatisfactory tests much greater due to limitations of the
Dacron swab used for anal Pap testing. Clinician sampling errors are
the main cause for failure to detect disease.
While the Pap test has decreased the rate of cervical cancer where
effectively implemented, it has not been successfully introduced in
resource-poor countries. There, available programs are opportunistic
and not well organized. Due to the relative lack of sensitivity of
the conventional Pap test, annual screening is necessary to detect
precancers before developing into cancers. Cancer can be universally
prevented when premalignant changes are detected early and treated
adequately. However, compliant and accurate surveillance, along
with proper diagnosis and treatment are required for this satisfactory
outcome.
HPV testing
Bimolecular testing for the presence of oncogenic HPV has been
incorporated into the cervical cancer screening and triage programs
in some resource rich nations [32-37].The reason for the change
is due to the relative insensitivity of the Pap test, the discovery of
oncogenic HPV as the causal agent for cervical cancer and supportive
results from clinical trials. Multiple HPV DNA and mRNA tests are
commercially available to detect multiple types of oncogenic HPV
or selective HPV types (i.e., HPV 16 and HPV 18). According to
American Society for Colposcopy and Cervical Pathology (ASCCP)
management guidelines, there are several uses for HPV testing [38].
HPV testing can be used either as a reflex triage test for women with
Austin J Biomed Eng 1(2): id1007 (2014) - Page - 03
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a typical Squamous Cells of Undetermined Significance (ASCUS)
results, as a triage test following therapy of HPV-related neoplasia,
in primary screening (co-testing) with the Pap test for women
greater than 30 years of age or perhaps as a single HPV multi-test for
screening purposes. Based on its very high negative predictive value
(99%) for excluding significant cervical neoplasias, there is growing
confidence in this test. When used as a primary screening test, greater
than 90% of all cases of CIN2/3 or cancer are detected [39]. Primary
screening with HPV tests is also approximately 25% relatively more
sensitive than cytology at detecting neoplasias. Unfortunately, the
positive predictive value of a single HPV test result for predicting the
presence of severe cervical neoplasia correctly is no greater than 20%.
In many cases, a positive test may simply indicate acute, subclinical
HPV infection (no detectable dysplasia), transmissible HPV from a
sexual partner or only a transient condition. Because the prevalence
of HPV is quite high in women 30 years of age or younger, its use is
limited primarily to older women.
Most HPV tests require sophisticated laboratory testing
and trained lab technicians. Furthermore, the tests are relatively
expensive and may not include all of the identified oncogenic HPV
types. However, because HPV DNA testing is more sensitive than Pap
testing, there may be a future role for affordable, simple, point-of-care
HPV tests in resource-poor locations [40].
Visual inspection with acetic acid (VIA)
Visual Inspection following Acetic acid application (VIA) consists
of a simple, contrast solution-enhanced visual inspection of the cervix
without use of special equipment [41-43].Cervical epithelial cells with
a high nuclear to cytoplasmic ratio (normal immature metaplasia and
all neoplasias) briefly appear white after exposure to 5% acetic acid
(vinegar). Following a one minute application of undiluted vinegar,
any resulting transient white epithelium noted on the ectocervix by
naked-eye examination is considered abnormal. Absence of a white
color or a normal pink/red color is considered a negative test result.
Individuals with limited medical experience can be trained to perform
VIA exams. Little equipment or supplies are needed, only vinegar,
cotton applicators, a light source and vaginal speculum. Visual
Inspection with Lugol’s Iodine (VILI) is similar, except 50% diluted
Lugol’s iodine is applied to the ectocervix of women not allergic
to iodine [44]. Normal native squamous epithelium and mature
metaplasia contain glycogen in the superficial and intermediate cell
layers. Iodine has an affinity for glycogen; hence normal epithelium
appears mahogany brown following the application. Normal

Figure 4: Cervical condyloma (indicated by the arrow) detected during
colposcopy. The long villous-like projections are a common morphologic
appearance of HPV-induced lesions(photo courtesy of Daron Ferris, MD).
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immature metaplasia and all neoplasias do not contain glycogen,
and therefore appear yellow following iodine application. Hence, a
brown color is considered a negative result and yellow a positive VILI
result. Improved sensitivity can be obtained if both VIA and VILI are
used concomitantly [44]. Because no special equipment is necessary,
VIA and VILI are considered inexpensive screening tests for cervical
cancer. They have proven somewhat effective at reducing cervical
cancer rates in resource-poor countries where no other screening
options are available. The sensitivity of VIA is similar to the Pap
test, but unlike the Pap test, it does not require specimen collection
or processing. Yet, there is substantial variability in the sensitivity of
VIA primarily due to experience, training and inherent weaknesses of
the test. According to some, the most efficient and effective strategy
to prevent cervical cancer in low-resource settings is to screen using
HPV testing or VIA, followed by treatment of the pre-cancerous
lesions using cryotherapy (freezing) [45,46]. This should optimally
be carried out in a single visit by physicians, nurses or midwives.
Until low cost HPV testing is realized, VIA or VIA with low power
magnification (VIAM) combined with cryotherapy may be the most
viable option for reducing the mortality associated with cervical
cancer in the developing world.
However, in a large study in India, HPV testing was associated
with a significant reduction in the number of women with advanced
cervical cancers and cervical mortality when compared with Pap
testing and VIA.[45]Others have also demonstrated the sensitivity of
VIA to be much less than the sensitivity of HPV DNA testing [41].This
inherent weakness of VIA and VILI is due to the same nonspecific
color reactions that occur in both normal and neoplastic epithelium.
The poor test specificity of VIA leads to many normal women,
particularly young women with an active transformation zone
(appears white with VIA testing), receiving unnecessary treatment.
VIA is also unable to examine the endocervical canal where many
neoplasias arise, particularly in postmenopausal women or women
using progesterone only contraception. As a consequence, VIA
suffers from the inability to determine exam adequacy (identification
of the entire squamo columnar junction and transformation zone),
discriminate epithelial and vascular changes, appraise positive
findings using intense illumination and magnification, and recognize
falsely positive diagnoses secondary to the presence of immature
metaplasia, repair or inflammation that also assumes a transient aceto
white, or in the case of VILI, a yellow color.
Diagnosis-colposcopy and biopsy

Figure 5: Cancer precursor (indicated by the arrow)seen by colposcopy.
The opaque white epithelium and coarsely dilated mosaic blood vessels are
diagnostic of CIN 3(photo courtesy of Daron Ferris, MD).
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Cervical cancer can be universally prevented when certain
premalignant lesions of the cervix are detected early and treated
adequately. However, compliant and accurate surveillance, along
with proper diagnosis and treatment are required for this outcome.
Colposcopy is the diagnostic procedure used following screening
tests to evaluate women with potential lower genital tract neoplasias
(Figure 4 and 5). The colposcope, astereoscopic binocular microscope
with a powerful light source, is used to detect cervical neoplasias and
to identify abnormal tissue for biopsy [16].The goal of colposcopy
is to identify cervical cancer precursors to enable eradication of
premalignant lesions in order to preclude their progression to cancer.
Cervical neoplasia exhibits certain morphologic features that can be
identified during a colposcopic examination [16].Findings from the
colposcopy exam and targeted biopsies determine subsequent patient
management.
Multiple cervical lesions of varied severity are frequently seen at
the same time and in the same patient (Figure 6). Normal anatomical
variants also mimic true disease. Discriminating levels of colposcopic
abnormality, and even normal from abnormal colposcopic findings,
requires ample clinical experience. Determining where to selectively
obtain small representative biopsies that reflect the worst disease is
a skill only acquired with rigorous training. However, colposcopy is
somewhat subjective and the quality of practice varies considerably.
Recent evidence suggests an urgent need to improve the accuracy
of colposcopy [47-55]. Without other viable solutions, it has been
recommended that multiple biopsies be obtained during colposcopy
to improve disease detection [56]. Yet, the collection of multiple
randomly obtained biopsies is also fraught with serious problems.
Proper colposcopy and cervical biopsy techniques are imperative
during the evaluation of women with cervical cytologic abnormalities.
Accurate cervical biopsy is the principal factor that ultimately
determines proper diagnosis and management. However, cervical
neoplasias identified by random biopsy may not actually represent
true cancer precursor lesions that require surgical intervention as
small, occult lesions may resolve spontaneously. Further, a random
biopsy approach risks histological overcall of normal epithelia
(immature metaplasia) that mimic neoplasia. Subsequent treatment

Figure 6: Multiple potential biopsy sites risks improper patient management.
This case depicts the potential ambiguity in selecting the most severe area
of neoplasia. Both a (small satellite lesion) and b (large 2 quadrant lesion)
represent CIN1. Because b is readily apparent, most colposcopists would
biopsy this site. An area of subclinical HPV infection is seen at d. The yellow
area e with dilated vessels mimics cancer, but merely represents a benign
Nabothi an follicle. The smaller lesion c is a true cancer precursor (CIN3).
If biopsies were incorrectly obtained from a, b, d or e, the patient would
receive no treatment. However, if c is biopsied, surgery is required to prevent
progression to invasive cancer (photo courtesy of Daron Ferris, MD).

Submit your Manuscript | www.austinpublishinggroup.com

Austin Publishing Group

would be unnecessary. Hence, there may be a role for sophisticated
novel technology to assist the identification and assessment of
cervical lesions.
Challenges of implementing current cancer prevention
strategies in developing countries
Because cervical cancer is preceded by premalignant cervical
intraepithelial neoplasia (CIN), if detected early and treated
adequately, cervical cancer can be universally prevented. However,
adequate resources for regular screening, appropriate diagnoses,
effective treatment and proper follow-up are required. Unfortunately,
for many women living in developing, resource-poor countries,
modern screening methods designed to detect precancerous cervical
disease are either not available or not affordable. Consequently,
cervical cancer is the number one cause of death from cancer for
women in these countries.
As previously discussed, the Pap test has been the gold standard
cervical screening test for many years. Where implemented on a serial
interval basis, cervical cytologic screening using conventional Pap
tests has significantly reduced the incidence of cervical cancer [57,58].
Yet, the highly complex Pap test system suffers from sampling,
laboratory and equipment errors, [59, 60] patient noncompliance,
[61] inappropriate interval screening, [62,63] inadequate follow-up of
abnormal Pap test results, [64,65] poor sensitivity, [66,67] and the need
for multiple (annual) testing and multiple patient visits. Moreover,
because of certain subjectivity, Pap test inter-observer reproducibility
is only fair (k=0.46) [68]. Liquid-based cervical cytology is more
sensitive in detecting cancer precursors than a conventional Pap test.
Yet, because it is considerably more expensive, requires complex
laboratory processing and equipment, and may not actually reduce
the incidence of cervical cancer in comparison with conventional
cytology, its utility in disadvantaged populations is suspect. Hence,
there has been a limited role for cervical cancer screening using a Pap
test in resource-poor regions. Moreover, when adopted in many of
these areas, the effectiveness has been disappointingly poor.
As a consequence of the limitations of both types of Pap tests,
other cervical cancer screening techniques have evolved. HPV DNA
and mRNA tests are more sensitive than the Pap test but less specific.
Unfortunately, these tests are cost prohibitive for resource-poor
nations. Moreover, testing is labor intensive, at risk to contamination
(PCR processing) and technically too advanced for rural settings.
In regions with poor or nonexistent cervical cancer screening
programs, the HPV vaccine offers the best option to reduce
the morbidity and mortality associated with anogenital and
oropharyngeal cancers. However, widespread implementation
is required, in addition to a reliable cold-chain transport system.
Presently, most resource-poor nations are critically challenged by
the cost of vaccination and lack of appropriate infrastructure. Rapid
global implementation is doubtful as evidenced even in resource rich
countries. Given a delayed adoption of HPV vaccination worldwide,
other novel means of cancer prevention are urgently needed. But
certain impediments, somewhat unique to resource-poor countries,
also challenge current HPV-induced cancer prevention efforts.
In resource-poor settings, barriers to cervical cancer screening
include lack of access to health care, shortage of quality medical centers
and laboratories, few trained and experienced personnel, distance
Austin J Biomed Eng 1(2): id1007 (2014) - Page - 05
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Figure7: Women awaitingmodern liquid-based Pap testing by CerviCusco in
the Andes Mountains of Peru (photo courtesy of CerviCusco, Peru).

to health care clinics, irregular or inconvenient hours of operation,
long waiting times, and lack of affordable options for follow-up care
(Figure 7). Individual and cultural barriers include lack of a tradition
of preventive health seeking behaviors, less exposure to medical
procedures, poor knowledge of cervical cancer, language barriers,
negative views of health care providers, lack of spousal support for
health care, anxiety and fear over potential serious diagnoses and
cancer, shortage of female healthcare providers, and modesty over
exposing the genital region [69]. Other factors include religious
beliefs, perceived lack of risk, embarrassment, and other competing
priorities (lack of time). Failure to obtain cervical cancer screening is
the major reason for developing cervical cancer (other than failure to
clear oncogenic HPV infection once infected). In fact in the United
States, 50% of all cases of cervical cancer are detected in women who
never have received adequate screening. The reasons for high cervical
cancer mortality rates are listed below:
•

Nearly nonexistent and otherwise ineffective Pap test
screening programs

•

Inability to afford a Pap test

•

Low priority for Ministry of Health – Competing health
problems

•

No national laboratory quality control or standards

•

Lack of properly trained personnel

•

Few modern materials, supplies and equipment

•

Absent infrastructure

•

Complex cancer prevention programs difficult to
coordinate

•

Unreliable power supply

•

Delay in Pap test results leading to noncompliance (loss
to follow up)

•

Paucity of experienced health care providers

•

Minimal access to care for screening, diagnosis and
treatment

•

Inadequate patient education

•

Most women diagnosed with advanced cervical cancer
when few treatment options are available and survival
rates are poor

Submit your Manuscript | www.austinpublishinggroup.com

Cervical cancer prevention is thus extremely challenged in
developing nations. However, anal cancer screening is virtually
nonexistent in resource-poor countries. Oral cancer screening
involves a rudimentary visual inspection and clinical palpation. Yet,
even in developed countries, this practice does not prevent oral cancer,
but only helps in early stage detection. Hence, the high mortality
rate of HPV-induced cancers in developing countries is largely due
to the fact that these countries do not have the appropriate medical
infrastructure and resources to support the organized screening and
diagnostic programs that are available elsewhere. Despite advances in
the prevention of cervical, anal and oral cancer with the introduction
of the HPV vaccine and attempts to deliver comprehensive cervical,
anal and oral cancer screening programs, women from developing
countries continue to experience health disparities for cervical
cancer morbidity and mortality. These health disparities between
women from developed and developing countries signal the need
for innovative approaches to reduce these disparities and improve
the quality of care and health. An accurate, well tolerated, widely
accessible, relatively inexpensive, simple and rapid on-site diagnostic
instrument to screen and triage women for anogenital and oral
neoplasias could reduce the incidence of cervical, anal and oral cancer,
particularly for inhabitants in resource-poor nations. Hence, because
of the many challenges to HPV-related cancer prevention described,
optical diagnostic techniques are necessary and may potentially solve
many of the current existing dilemmas encountered in the effort to
reduce these preventable cancers.
Optical diagnostics
Numerous optical diagnostic techniques have been developed in
the last two decades for the detection of epithelial cancers, such as
those in the oropharynx and anogenital regions. These techniques
include optical coherence tomography (OCT), reflectance imaging,
diffuse reflectance spectroscopy (DRS), fluorescence imaging,
and smart phone based diagnostic devices. Here we briefly review
OCT and reflectance imaging, but focus our discussions on DRS,
fluorescence imaging, and smart phone based diagnostic devices for
the potential in resource-poor settings.
OCT
OCT is a new optical technology for performing high-resolution,
noninvasive cross-sectional imaging in biological systems [70]. It
uses low-coherence interferometry to produce a 2D image of tissue
microstructures in a way that is analogous to ultrasonic imaging.
OCT was originally developed for retina imaging, but has recently
been extended for oral, cervical and rectal cancers. Lee et al. [71]
acquired OCT images of normal and precancerous oral mucosa and
demonstrated to the use of the thickness of epithelium to achieve
a sensitivity and specificity 82 and 90%, respectively. A literature
review by Ovari et al., [72] indicated that OCT is a reliable method
for identifying and targeted biopsy of inflammated, pre-malignant
or cancer tissue in human laryngeal and pharyngeal mucosa. Liu
et al., [73] investigated the use of OCT as an adjunct to colposcopy
in the detection of CIN 2+ cervical neoplasia in a real-time clinical
evaluation and increased the specificity from 83% to 93%.Gallwas
et al., [74] evaluated the accuracy and reproducibility of OCT in the
characterization of cervical intraepithelial neoplasia (CIN) and to
distinguish between different CIN grades. They concluded that OCT is
highly sensitive in identifying pre-invasive and invasive cancer of the
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Figure 8: Illustration of the principle of diffuse reflectance spectroscopy with a fiber optic probe and the spectrum analysis procedures.

uterine cervix. Zhang et al., [75] quantified the scattering coefficient
of OCT images of rectal tissue by curve fitting the OCT signals to a
confocal single model and demonstrated it as a promising diagnostic
criterion of early rectal cancer. While OCT can provide high
resolution 2D or 3D images of tissue structure and has significantly
improved retina imaging, its application for oral, cervical and anal
cancer detection in resource-poor settings is limited due to its high
cost ($60,000 to $80,000) [76] and the need of experienced physician
to interpret the images.
Reflectance imaging
Reflectance imaging, such as confocal microscopy and spectral
imaging has found applications in oral, cervical and anal cancer
screening and detection. Clark et al., [77] characterized features
of normal and neoplastic oral mucosa in 15 biopsy pairs from 17
patients using reflectance confocal microscopy. Carlson et al., [78]
used confocal reflectance microscopy on ex vivo cervical biopsies
and in vivo cervical tissue to image the morphologic and biochemical
changes associated with precancer. Wang et al., [79] demonstrated a
MEMS micromirror enabled handheld confocal imaging probe for
portable oral cancer detection with a large field of view. Roblyer et al.,
[80] designed a multispectral digital microscope with fluorescence,
narrow-band reflectance, and polarized reflectance modes as a tool
to improve detection of oral neoplasia. Subhash et al., [81] developed
a diffuse reflectance imaging system which captures monochrome
images of a patient’s mouth at 545 and 575 nm that were used to identify
the margins of an oral lesion during invasive surgical interventions.
Reflectance imaging system can potentially be made portable and
cost-effective so that it could be used in developing countries [79].
However, remote image interpretation may be required to achieve an
accurate diagnosis due to the lack of experienced imaging specialist
in low-resource regions.
DRS
DRS, also known as elastic scattering spectroscopy (ESS), is a
non-destructive technique designed to measure the absorption and
Submit your Manuscript | www.austinpublishinggroup.com

scattering properties of turbid media, such as biological tissues [8292]. In DRS, a beam of broadband light emitted from a light source,
such as thermal lamp, white LED or laser diodes, is launched into a
tissue, often through multimode optical fibers, as illustrated in Figure
8 (upper left). The photons propagating in the tissue may experience
various events, including elastic scattering, Raman scattering,
absorption and fluorescence. Some of these photons escape from
the tissue surface, after multiple elastic scattering, as reflectance. A
detector, often a multimode optical fiber or fiber bundle, collects a
portion of the reflectance and relay it to anoptical spectrometer,
where the photons are converted to a wavelength-dependent intensity
distribution of electrons, termed diffuse reflectance spectrum (upper
right). The reflectance spectrum is analyzed using a model of photon
propagation in tissue (e.g., diffusion equation, [82,93,94] Monte
Carlo simulation, [95-98] or empirical model.[99]) to extract the
absorption and reduced scattering coefficients (µa(λ) and µs’(λ)), as
shown in Figure 8 (lower right). From the absorption spectrum, the
concentrations of the absorbers (such as oxy-hemoglobin, deoxyhemoglobin, beta-carotene and melanin, etc.) can be computed using
the Beer–Lambert law (also known as Beer’s law).The scattering
reflects the tissue morphological information, such as nuclear size and
density. Both tissue compositions and morphological information
have been identified as useful biomarkers for cancer diagnostics.
DRS in the visible wavelength range (VIS-DRS) is sensitive to the
absorption and scattering properties of epithelial tissue and has shown
promise for early diagnosis of cancers in the cervix and oral cavity [101116]. The absorption and scattering properties of epithelial tissues
reflect their underlying physiological and morphological properties
[117]. In the visible band, dominant absorbers in oral and cervical
tissue are oxygenated (HbO2) and deoxygenated hemoglobin (Hb),
arising from blood vessels in the stroma. Light scattering is primarily
caused by cell nuclei and organelles in the epithelium and stroma,
as well as collagen fibers and cross-links in stroma. Neoplastic tissue
exhibit significant changes in their physiological and morphological
characteristics that can be quantified optically: Stromal layer
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absorption is expected to increase with angiogenesis, whereas stromal
scattering is expected to go down with neoplastic progression as
extracellular collagen networks degrade [96,103,117-120]. Epithelial
scattering has been shown to increase due to increased nuclear size,
increased DNA content, and hyperchromasia [96,117,118,121]. VISDRS have a penetration depth that can be tuned to be comparable
to the thickness of the epithelial layer or deeper to probe both the
epithelial and stromal layers [109,117,122]. Therefore, VIS-DRS have
a great potential to be used as a cost-effective, fast and sensitive tool
for diagnosis of early precancerous changes in the oropharynx and
anogenital regions.
Current DRS systems typically consist of a broadband source,
a spectrometer for multi-spectral detection and a fiber-optic probe
for relaying light to and from the instrument [123]. The fiber-optic
probe allows for contact measurement which provides access to many
internal organ sites and a well-defined penetration depth. Contact
measurement can also avoid specular reflection from the tissue surface
which does do not carry any useful tissue information. However, the
contact DRS systems have not been specifically designed to be robust
and reliable, especially in resource-poor settings. Potential sources
of systematic or random errors can arise from the uncontrolled
probe-tissue interface and the lack of robust, real-time calibration
technique. The lack of a robust, real-time calibration technique makes
the calibration process time-consuming and potentially inaccurate,
particularly when attempting to quantify absolute absorption and
scattering coefficients. The uncontrolled probe-to-tissue coupling
and pressure can make it difficult to obtain a reproducible and intact
tissue reflectance spectrum. It is generally believed that the changes
may be attributed to the compression of the blood vessels which
causes reduced blood flow and alterations in the metabolism of the
tissue as well as a change in the density of the scatterers [124-132]. It
is therefore critical to measure and control the probe contact pressure
in order to obtain reproducible and intact tissue physiological
parameters.
More importantly, most VIS-DRS systems use thermal light
sources, grating spectrographs, and cooled CCD cameras. Thermal
light sources have large footprint, short life-time, low power
efficiency, and low coupling efficiency to optical fibers. Spectrometers
using grating spectrographs and cooled CCD cameras have extremely

(a)

(b)

Figure 9: (a)Photograph of thesmart fiber-optic sensor system[100](Reprinted
with permission. Copyright Optical Society of America 2014);and (b) a
demonstration how the smart sensor is used with a speculum for cervical
cancer detection.
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high wavelength resolution and sensitivity, but are very bulky
and expensive and consume a large amount of electrical power. In
addition, a stable power supply is very often required to operate a
thermal lamp and a CCD camera. The system complexity also makes
it necessary for the operator to have extensive knowledge in optical
spectroscopy and professional training on the instrument and probes.
Taken together, it is very difficult for VIS-DRS systems in their
current forms to be directly used for cancer screening in resourcelimited settings.
Yu et al. recently reported the development of a smart fiber-optic
probe based on a portable DRS instrument, shown in Figure 9, for oral
and cervical cancer detection in developing world [100,133]. The smart
fiber-optic sensor integrated a VIS-DRS channel, a self-calibration (SC)
channel, and a diaphragm-based fiber-optic interferometric (DFPI)
pressure sensor into a single fiber-optic probe to eliminate operator
bias and to reduce size and power consumption as well as the need of
operator training. The VIS-DRS channel measures the quantitative
information about tissue physiological and morphological properties.
The SC channel records a calibration spectrum in concurrent with
the collection of a tissue reflectance spectrum. By dividing the tissue
reflectance spectrum by the SC spectrum, the sources of errors due
to light source drift and fiber bending loss can be removed in realtime. The pressure sensor provides real-time feedback on the probe
pressure so that the operator can manually adjust the force applied on
it. The device also used state-of-the-art photonics components, such
as LEDs and miniature spectrometers, to reduce the size and power
consumption, and automated Lab VIEW software to reduce the need
of operator training. Therefore, it has a great potential as an accurate,
fast, cost-effective and robust tool for detection of oral, cervical and
anal cancers in resource-poor settings. The device has been tested
for characterizing pressure response of oral mucosal tissue in vivo in
healthy volunteers. Clinical validation of the device in a low-resource
setting is necessary for identifying contrasts in optical biomarkers
that vary with different grades of cervical intraepithelial neoplasia
from normal cervical tissues.
Fluorescence imaging
Fluorescence imaging is a powerful spectro chemical method that
has been widely used for imaging of endogenous fluorophores, such
as Collagen, FAD and NADH, or contrast agents (or photosensitizers)
in biological tissue. In fluorescence imaging molecules of the analyte
are excited by light at a certain wavelength and emit light of a longer
wavelength. Fluorescence imaging features very low detection
limits and high molecular sensitivity and specificity. A number
of studies have investigated the use of fluorescence imaging for
screening and detection of cancers in the oropharynx and anogenital
regions [118,134-138]. Shin et al., [139] reviewed recent advances
in fluorescence imaging techniques to detect oral cancer and its
precursors, while The kkek et al., conducted a detail review on optical
imaging, including fluorescence imaging, for cervical cancer detection
as a global problem [140]. Here we focus on two emerging low-cost
imaging solutions, a high resolution micro endoscope (HRME) and
a fluorescence goggle.
HRME
In 2011 Pierce et al. [141] reported the development of a low-cost
HRME that can collects fluorescence images through a fiber-optic
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imaging bundle. The HRME employs a blue LED as its excitation
source, a fiber-optic imaging bundle with 30,000 pixels for tissue
illumination and fluorescence collection, and a CCD camera for
image detection. It was claimed that the system can be built in a day
using commercial components for under US$5,000. Pierce et al. [142]
have conducted a pilot clinical study in China in 2012 to evaluate the
HRME system for identifying women with cervical precancers. In
the 174 women enrolled in the study, 69 sites appearing abnormal
on colposcopy among which 12 showed CIN2+ on pathology. By
quantification of the nuclear-to-cytoplasm ratio from the collected
HRME images all the 12 pathology abnormal sites and 38 of the
remaining 57 pathology normal sites were classified. The HRME also
accurately classified all positive sites for high-risk HPV DNA. For the
HPV positive sites which were found either normal by colposcopy
or showed < CIN2 on pathology, only 6/32 (18.8%) were classified
as abnormal by HRME. The study suggested that evaluation of
suspicious lesions by HRME may increase the efficiency of current
see-and-treat programs for cervical cancer.
Wearable Fluorescence Imaging System
Liu et al. [143-146] developed a compact wearable near-infrared
imaging system (fluorescence goggle) as an intraoperative tool for
tumor detection and surgical guidance. Surgeons conventionally rely
on pre-operative imaging technologies to guide surgical procedures.
The system, as shown in Figure 10, is portable, small and userfriendly. Unlike conventional systems, the near-infrared fluorescence
information is imaged in real time and displayed in the wearable
eyepieces. Therefore, the point of view of the surgeon and that of the
imaging system are aligned. To achieve fast imaging without motion
artifacts, CMOS sensor technology has been applied in fluorescence
goggle systems.
In conjunction with targeted molecular probes, it has been shown
that fluorescence goggles accurately detect many forms of tumors
including breast tumors and liver tumors, in small animal models
[143-145]. Sub-millimeter nodules that are not obvious to unaided
eye can be detected by fluorescence goggle. Recently, the prototype
fluorescence goggle has been translated from the bench top into
clinical surgical studies for hepatocellular carcinoma (HCC) [146].
The extension of tumors can be well visualized under the aid by
florescence goggles [146]. In addition to guiding surgical resections,
fluorescence goggles can also guide biopsy and staging procedures
such as the sentinel lymph node biopsy. For instance, it can guide
sentinel lymph node biopsy, a standard cancer staging procedure
for many cancer forms [143,144,146]. The fluorescence goggles are
compatible with many forms of contrast agents, including clinically
approved indocyanine green and emerging agents such as quantum
dots [143-146].
Studies have been successfully conducted to prove the feasibility
of using the fluorescence goggle systems at the point of care [143].
For this purpose, the goggle has been integrated with wireless
communication technologies. Using the wireless-capable fluorescence
goggle, an experienced physician can guide the assessment of cancer
from remote sites. In a preclinical study, the functional status of the
tumor are imaged by a veterinarian performing the fluorescenceguided surgical procedures and simultaneously transferred wirelessly
to the computer of a remote expert [143]. The video was displayed in
real time, enabling remote assistance. Based on the data transmitted,
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the remote expert interacted verbally in real-time with the veterinary
surgeon in the lab through a mobile phone to guide the surgery.
Tumors were successfully located and removed under the wireless
collaboration and the functional information of tumor status was
stored at a remote computer. While the reported study simplifies
clinical conditions, it demonstrates the potential of fluorescence
goggles for telemedicine and point-of-care applications.
The fluorescence goggle platform has been applied to guiding
breast and liver cancer surgeries, which showed the feasibility of
using the system to guide oncologic interventions. In the future,
the fluorescence goggle technology can be potentially applied to
management of cervical, anal and oral cancer, in both developed
countries and developing countries. The fluorescence goggles are
cost-effective solutions for low resourced settings. It has been
reported that prototype goggles can be constructed at a cost as low
as $1,200. The affordable nature of fluorescence goggles renders them
promising candidates for the screening as well as an intraoperative
tool in the treatment of oral, cervical and anal cancers in rural
areas and developing countries. They also hold great potential for
expanding the current reach of image-guided interventions to
currently underserved areas.
Smartphone based diagnosis
Smartphones represent one of the most exciting consumer
electronics devices that have significantly changed the way people
communicate during the past decade. Smartphones today, offer
enormous computation power on a very compact platform.
Moreover, they are integrated with some key features such as
wireless communication, camera, global positioning systems (GPS),
gyros, and accelerometers etc., which improve its functionality in an
integrated manner. As a direct result of the versatility of smartphones,
they are also playing a growing role in optical imaging for medical
and biological applications, such as for spectroscopy, [147-150]
microscopy, [149,151] counting molecules, [152] fluorescence
imaging of single nanoparticles and viruses, [153] and cell-monitoring
platform through lens less imaging [154].
The cost of wireless technology has also decreased over the
years, thereby making smartphones a more affordable device. The
number of smartphones has increased tremendously throughout the
world in the last 5 years. Based on an UN report, there are currently
6.8 billion smartphones subscribers all over the world. More

Figure 10: Fluorescence goggle systems: (A) schematic illustration of
the concept;[143](Reprinted with permission. Copyright Elsevier 2011) and
(B) picture of a prototype fluorescence goggle system.[144] (Reprinted with
permission. Copyright SPIE 2013).
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importantly, the report claims that the rate of cell phone diffusion
into developing countries is at 89% as compared to 96% globally.
This suggests smartphone-based diagnosis could potentially reduce
healthcare costs, provide access to advanced laboratories through
wireless communication to remote parts of the world, and be a fielddeployable means for diagnosis, etc. Smartphones in healthcare could
revolutionize the field of telemedicine and point-of-care devices for
diagnostics. Some of the noted advantages of using smartphones as
diagnostic tools include:
•

Readily available sensors such as cameras (CMOS/CCD),
gyros, accelerometers, GPS, magnetic field sensing etc.

•

Computational
power
for
computational-based
applications such as lens less imaging.

•

Handheld, cost-effective, portable device for point-ofcare diagnostics in a limited-resource setting.

•

Availability of advanced treatments to remote parts of the
world.

•

Networking of the data gathered, through wireless
communication.

•

Data uploaded to central servers wirelessly can be used
to create spatio-temporal maps of various conditions
visualized in real time. Thereby, realizing a distributed
sensing approach which allows for application of
smartphones for disease surveillance and management as
well as epidemiologic studies in general.

•

Most Smartphone-based devices consist of an accessory
which could be attached to a smartphone. Such an
arrangement allows for the use of different accessories
to realize different diagnostic tools on a single cellular
device.

Almost all of the smartphone-based devices that have been

reported so far are realized through the attachment of an external
module to smartphones. The external modules usually make use of
the Smartphone’s camera. More importantly, it is the design of these
external modules/attachments that determines the functionality of the
smartphone-based device as a whole. Some of the external modules/
attachments for the Smartphone’s camera and their applications are
discussed below:
External modules for Spectroscopy
The main objective for this external module would be to
decompose the incoming light into its spectral components. One
such module proposed by Smith et al. [149] consists of a collimating
tube with slits on both ends Figure 11(a). The first slit (the one closer
to the sample) controls the resolution of the spectrometer. Better
resolutions could be obtained by minimizing the aperture of the first
slit. The second slit, in this case was fixed at 1 mm. The second slit
forms the aperture for the diffraction grating where light is split into
its respective components and is captured by the smartphone camera.
The spectral components are then quantified from the captured
image. Gallegos et al, [155] demonstrated the use of a smartphone
spectrometer as the detection instrument for a label-free photonic
crystal biosensor and has achieved 0.009nm accuracy in measuring
shifts in the resonant wavelength of the sensor. Public Lab introduced
a smartphone spectrometer kit at the price of $70 [156]. Wang et al.
[148] has proposed different ways for implementing smartphonebased spectroscopy. A few of their designs for externals modules
include techniques using rotating optical filter wheels, acoustooptical tunable filter (AOTF), liquid crystal tunable filter (LCTF), and
diffraction grating. It is important to note that spectral images could
be obtained by using filters such as rotating filter wheels.
External module for Fluorescence imaging of single nanoparticle
Wei et al. [153] used a field-portable fluorescence microscopy
platform installed on a smartphone for imaging of individual
nanoparticles as well as viruses. The external module used in the

Figure 11: (a)System diagram for a smartphone-based spectrometry.[149] (Reprinted with permission. Copyright Optical Society of America 2011); (b) Ray-tracing
diagram of the smartphone microscope is shown, where excitation and scattered beams are indicated with solid blue rays, while the fluorescent emission is
highlighted with solid green rays.[153] (Reprinted with permission. CopyrightAmerican Chemical Society 2013)(Permission to reuse to be obtained from ACS) (c)
Smartphone-based microscopy, an optical layout forfluorescence imaging. The same apparatus can be used for brightfield imaging, with the filters and LED
removed.[157] (Reprinted with permission. CopyrightPLOS ONE 2009).
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platform houses a compact laser-diode-based excitation at 450 nm
that illuminates the sample plane at a high incidence angle, a longpass (LP) thin film interference filter, an external low NA lens, and a
coarse mechanical translation stage or focusing and depth adjustment
Figure 11(b).The low NA (numerical aperture) external collection
lens rejects the oblique illumination light on the sample plane. The
scattered light from the sample plane is filtered by the LP filter, acting
as a background rejection mechanism which is necessary to isolate
the weak fluorescent signal arising from individual nanoparticles or
viruses (on the sample plane). The low NA imaging system is also
reduces the alignment sensitivity to depth of field, such that a coarse
mechanical translation stage could be sufficient to focus the cell
phone microscope to the sample plane.
External modules for Microscopy
One of proposed designs for smartphone-based microscopy
is discussed here. Breslauer et al. [157] reported a system using a
0.85 NA 60×achromatic objective and a 20x wide-field microscope
eyepiece. A schematic diagram of the system is as shown in Figure
11(c). The resulting system features a field-of-view of 180 mm
diameter, an effective magnification of 28× onto the camera face and
a measured spatial resolution of 1.2 mm. This system could be used
both for bright field microscopy and fluoroscopy (using fluorescence
filters as shown in the figure).
Many other external modules have also been reported in
the literatures but only a few of them have been discussed here
for conceptual purposes. Key applications such as spectroscopy,
microscopy and fluorescence imaging have been demonstrated
with smartphone-based devices which show the potential for costeffective, point-of-care diagnostic tool with wireless communication.
Smartphone-based microscopy has been used for observing blood
smears, imaging tuberculosis, imaging malaria and sickle-cell anemia
[157]. Smartphone-based spectroscopy has been used to observe
the transmission spectra from a finger [149]. However, current
smartphone-based device accessories lack the integration of a fiberoptic attachment which would provide ease of access to cervical,
oral and anal cancer sites. Advancements in both smartphones and
external modules/attachments could provide a more robust device
for diagnosis. Although, Wang et al. [148] mentioned a fiber-optic
external module which could collect the diffuse reflectance, very
limited information has been reported in the literatures about the use
of an external fiber optic module with smart-phones.
In conclusion, smartphone-based devices show great potential for
point-of-care diagnostic tool that is particularly useful for cervical,
oral and anal cancer detection in developing countries. Realization of
fiber-optic external modules needs to be explored which could open
the doors for smartphone-based endoscopy and optical diagnostics.

Summary
Despite many improvements over the last decades, prevention,
screening and diagnostic tests of cancers in the oropharynx and
anogenital regions remain a huge challenge in developing countries
and resource-poor areas. This is mainly due to the lack of appropriate
medical infrastructure, expensive resources and well-trained
personnel to support the organized screening and diagnostic programs
that are available in the developed world. Emerging optical diagnostic
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techniques, especially VIS-DRS, reflectance and fluorescence imaging
as well as smartphone based devices, are noninvasive technologies
that have shown great potential as a cost-effective and fast tool for
diagnosis of early precancerous changes in the cervix, oral cavity and
anus. Among these techniques, VIS-DRS with a fiber-optic probe is
one of the few that can provide quantitative diagnosis about tissue
optical and physiological properties. Portable fluorescence imaging
systems is another promising candidate for addressing the current
challenges. Smartphone based devices are likely to play an increasing
role in the near future.
The high resolution and sensitivity offered by optical diagnostic
techniques make them promising solutions to the health problems
related to oral, cervical and anal cancers in resource poor settings.
The cost consideration also favors optical techniques, as they can be
manufactured with low cost. With available photonics technologies,
miniature CCDs and spectrometers can now be manufactured and
integrated into optical diagnostic systems at low cost, provided that
there is enough need. Modular design is another effective approach
to reduce the system complexity and associated cost. In fact, turning
massively available spare smartphones into diagnostically useful
optical imaging or spectroscopy devices has been a hot research topic
of the recent Global Health programs at NIH as well as the Bill &
Melinda Gates Foundation.
Despite of the encouraging progress in the past decade, optical
diagnostic techniques for developing countries are still in their
nascent research stage. More coordinated efforts from individual
research groups as well as related industries are needed to move
these techniques forward. In addition, the use of optical imaging and
spectroscopy will be primarily compatible with assessable organs due
to the limitation of light penetration in deeply embedded tissues.
In the next stage of development, it will be likely that the research
community will establish a common calibration standard, which
will enhance the quality control and clinical systems. From this
point of view, the smart fiber-optic sensor device which includes a
self-calibration and a pressure channel is an important step towards
the goal of obtaining consistently calibrated and quantitative
measurements that can be compared across different studies from
different groups.
Larger scale clinical studies to compare sensitivity and specificity
of optical techniques with that of the gold standard, such as pathology,
are also needed to facilitate the clinical translation of various optical
systems. The cost evaluation of optical techniques versus traditional
smear test needs to be evaluated. In low-resource settings, the “valuedriven engineering” approach may help us better understand the
advantages of disadvantages of new optical techniques.
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